Efficacy study by intensive Leukocytapheresis

Efficacy study by intensive Leukocytapheresis - Multicenter cohort study of Leukocytapheresis (LCAP) for Ulcerative Colitis (Kanagawa LCAP Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005293

Enrollment

Registered

2011-03-23

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Interval of LCAP : 2 times/week for 2 weeks and 1 time/week for after 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with refractory moderate to severe active ulcerative colitis who needs LCAP

Exclusion criteria

Exclusion criteria: The treatment with immunomodulator (azathioprine, 6-MP, tacrolimus and cyclosporine), anti-TNF alpha agents and angiotensin-converting enzyme inhibitor

Design outcomes

Primary

Measure	Time frame
Clinical remission by partial Mayo score and average terms until clinical remission.	—

Secondary

Measure	Time frame
1.Clinical improvement rate by Lichtiger's CAI 2.Changing a Steroids dosage before and after LCAP	—

Countries

Japan

Contacts

Public ContactYUTAKA ENDO, M.D.

Showa University Fujigaoka Hospital Division of Gastroenterology

Y_endo2004@yahoo.co.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026